After yesterday’s prostate cancer rant, I was pleased to see some good prostate cancer news from GlaxoSmithKline. GSK has filed a sNDA with the FDA for Avodart (dutasteride) reducing the risk of prostate cancer in men who are already at risk of developing prostate cancer. That’s good news.
However, given the FDA’s war on men and their refusal to help men with prostate cancer, I’m very cautious that GSK’s claim will be approved.
Reference: GSK press release
